Denali therapeutics reports third quarter loss per share of $0.48

Denali therapeutics reports third quarter 2019 financial results and business highlights.denali therapeutics inc - cash, cash equivalents, and marketable securities were $502.9 million as of september 30, 2019.denali therapeutics inc qtrly loss per share $0.48.

DNLI Ratings Summary

DNLI Quant Ranking